Study of Severe Hepatitis Treated with a Hybrid Artificial Liver Support System

Artificial liver support system (ALSS) has been used to treat hepatic failure and has significantly decreased the mortality. TECA hybrid artificial liver support system (TECA-HALSS), which combines the hollow fiber bioreactor with a plasma exchange circuit, was used to assess the efficacy, safety and feasibility in treating severe hepatitis patients. The hybrid artificial liver support system (HALSS) consists of a bioreactor containing more than 5 ×109 porcine hepatocytes and plasma exchange device. Fifteen patients with severe hepatitis were treated with this hybrid system. All patients experienced a reduction in symptoms such as fatigue, abdominal distention or ascites. After each treatment serum total bilirubin decreased markedly while prothrombin activity increased. There were ten patients whose progress of hepatocyte necrosis was stopped after HALSS treatment, and finally they recovered completely. One patient received liver transplantation after HALSS therapy and survived. No serious adverse events were noted in the fifteen patients.

[1]  Keizo Sugimachi,et al.  Hybrid-artificial liver support system. , 2002, Surgery.

[2]  P. Malchesky,et al.  Artificial liver. State of the art. , 1991, Digestive diseases and sciences.

[3]  P. Seglen.  Preparation of isolated rat liver cells. , 1976, Methods in cell biology.

[4]  A. Friedman.  Why bioartificial liver support remains the Holy Grail. , 1998, ASAIO journal.

[5]  Melanie E. Goward,et al.  Multiple Groups of Novel Retroviral Genomes in Pigs and Related Species , 2001, Journal of Virology.

[6]  K. Boudjema,et al.  Auxiliary versus orthotopic liver transplantation for acute liver failure. EURALT Study Group. European Auxiliary Liver Transplant Registry. , 1999, Journal of hepatology.

[7]  E. Friedman.  Vascular access for hemodialysis: still the limiting component of a life sustaining regimen. , 1998, ASAIO journal.

[8]  G. Abouna,et al.  Extracorporeal liver perfusion system for successful hepatic support pending liver regeneration or liver transplantation: a pre-clinical controlled trial. , 1999, Transplantation.

[9]  C. Mullon,et al.  Evidence of absence of porcine endogenous retrovirus (PERV) infection in patients treated with a bioartificial liver support system. , 1999, Artificial organs.

[10]  J. Neuberger,et al.  A Bioartificial Liver--State of the Art , 2002, Science.

[11]  M. Shimada,et al.  Mass Preparation of Primary Porcine Hepatocytes and the Design of a Hybrid Artificial Liver Module using Spheroid Culture for a Clinical Trial , 2001, The International journal of artificial organs.

[12]  S. Bhatia,et al.  Advances in bioartificial liver devices , 2001, Hepatology.

[13]  G. Mazariegos,et al.  Clinical and laboratory evaluation of the safety of a bioartificial liver assist device for potential transmission of porcine endogenous retrovirus. , 2002, Transplantation.

[14]  V. Cuervas-Mons,et al.  In vivo efficacy of a bioartificial liver in improving spontaneous recovery from fulminant hepatic failure: a controlled study in pigs. , 2000, Transplantation.

[15]  N. Sussman,et al.  The Hepatix extracorporeal liver assist device: initial clinical experience. , 1994, Artificial organs.

[16]  Philippe Ichai,et al.  Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation. , 2002, Transplantation.

[17]  S. Kawasaki,et al.  Living‐related liver transplantation for patients with fulminant and subfulminant hepatic failure , 1999, Hepatology.

[18]  G. Mazariegos,et al.  Acute liver failure: Clinical features, outcome analysis, and applicability of prognostic criteria , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[19]  J. Patzer,et al.  Advances in Bioartificial Liver Assist Devices , 2001, Annals of the New York Academy of Sciences.

[20]  Friedman Al.  Why bioartificial liver support remains the Holy Grail. , 1998 .

[21]  U Marx,et al.  European research and commercialisation activities in the field of tissue engineering and liver support in world wide competition , 1998, The International journal of artificial organs.

[22]  X. Xiaowei,et al.  Severe hepatitis treated with an artificial liver support system , 2001, The International journal of artificial organs.

[23]  M. Maggard,et al.  Liver transplantation for fulminant hepatic failure in the pediatric patient. , 1998, Archives of surgery.

[24]  William M. Lee,et al.  Acute hepatic failure: A Western perspective , 2000, Journal of gastroenterology and hepatology.

[25]  K Sugimachi,et al.  Hybrid artificial liver using hepatocyte organoid culture. , 2001, Artificial organs.

[26]  I. Sauer,et al.  Development of a Hybrid Liver Support System , 2001, Annals of the New York Academy of Sciences.

[27]  A. Demetriou,et al.  Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. , 1997, Annals of surgery.

[28]  E. Keeffe,et al.  Resection versus transplantation for hepatocellular carcinoma , 1999, Journal of Gastroenterology and Hepatology.

[29]  W. Arnaout,et al.  Use of a novel bioartificial liver in a patient with acute liver insufficiency. , 1993, Surgery.

[30]  A. Shakil,et al.  Fulminant hepatic failure , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.